GlassScriptPhysician profile
Alison Raybould
NPI 1487034955
$1,010.26
in general payments reported to CMS, 2019-2025
19 companies · $193 in 2025
The $193 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $696 · 2024: $122 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $896 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $895.52 |
| Education | $114.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $152.05 | 2023-2025 | Imfinzi, Lynparza |
| Ipsen Biopharmaceuticals, INC | $121.59 | 2024 | Onivyde |
| Exelixis INC. | $118.46 | 2023 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $116.75 | 2023 | |
| Astellas Pharma US INC | $99.95 | 2023 | |
| Eisai INC. | $63.80 | 2023 | |
| Caris Mpi, INC. | $60.94 | 2025 | Mi Cancer Seek |
| Taiho Oncology, INC. | $38.24 | 2023 | |
| Beigene USA, INC. | $31.00 | 2023 | Brukinsa |
| Mylan Institutional INC. | $26.06 | 2023 | Fulphila, Ogivri |
| Pharmacyclics LLC, An Abbvie Company | $24.20 | 2023 | Imbruvica |
| Puma Biotechnology, INC. | $23.03 | 2023 | |
| Abbvie INC. | $22.92 | 2023 | |
| Seagen INC. | $21.72 | 2023 | Padcev |
| Adaptive Biotechnologies Corporation | $21.40 | 2025 | Clonoseq |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $20.15 | 2023 | Lorbrena, Braftovi, Mektovi |
| G1 Therapeutics, INC. | $16.91 | 2023 | Cosela |
| Pfizer INC. | $16.23 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.86 | 2023 | Opdivo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Raybould listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.